{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T12:37:32Z","timestamp":1754483852856,"version":"3.41.2"},"reference-count":31,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,5,31]],"date-time":"2022-05-31T00:00:00Z","timestamp":1653955200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>To examine the effects of apalutamide on endocrine function and flare prevention in metastatic hormone-sensitive prostate cancer (mHSPC) patients administered GnRH agonists.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The first newly diagnosed mHSPC patient took apalutamide for 2 weeks followed by combination with GnRH agonist, as recommended by clinical guidelines. Serum luteinizing hormone (LH), testosterone, and PSA were detected during the oral administration of apalutamide before and after ADT. Eight newly diagnosed mHSPC patients innovatively took apalutamide 1 hour before GnRH agonist administration; LH, testosterone and PSA were detected before and after ADT.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In the first patient, LH and testosterone levels were increased during apalutamide monotherapy, and serum PSA levels decreased rapidly, demonstrating apalutamide effectively blocked AR signaling. In patients on the 1-hour regimen, combined treatment with apalutamide and GnRH agonists led to peak level of testosterone on day 3 and castration level on day 28, while PSA decreased continuously. No one experienced dysuria or bone pain worsen after ADT.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Taking apalutamide 1 hour in advance may effectively prevent the flare-up effect in prostate cancer patients treated with GnRH agonists. Compared with the 2-week regimen, the 1-hour regimen could simplify the treatment process and bring testosterone to castration levels in advance.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2022.878264","type":"journal-article","created":{"date-parts":[[2022,5,31]],"date-time":"2022-05-31T04:52:27Z","timestamp":1653972747000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Absence of PSA Flare With Apalutamide Administered 1 Hour in Advance With GnRH Agonists: Case Report"],"prefix":"10.3389","volume":"12","author":[{"given":"Zhiquan","family":"Hu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhenghao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiyuan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xing","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhihua","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunguang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,5,31]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1800536","article-title":"Enzalutamide in Men With Nonmetastatic, Castration-Resistant Prostate Cancer","volume":"378","author":"Hussain","year":"2018","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1209096","article-title":"Randomized Phase 3 Trial of Abiraterone Acetate in Men With","volume":"368","author":"Ryan","year":"2013","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2008.08183.x","article-title":"The Efficacy and Safety of Degarelix: A 12-Month, Comparative, Randomized, Open-Label, Parallel-Group Phase III Study in Patients With Prostate Cancer","volume":"102","author":"Klotz","year":"2008","journal-title":"BJU Int"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2020.09.046","article-title":"EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Part II-2020 Update: Treatment of Relapsing and Metastatic Prostate Cancer","volume":"79","author":"Cornford","year":"2021","journal-title":"Eur Urol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30102-4","article-title":"Conventional Versus Hypofractionated High-Dose Intensity-Modulated Radiotherapy for Prostate Cancer: 5-Year Outcomes of the Randomised, non-Inferiority, Phase 3 CHHiP Trial","volume":"17","author":"Dearnaley","year":"2016","journal-title":"Lancet Oncol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1056\/NEJMoa1903307","article-title":"Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer","volume":"381","author":"Chi","year":"2019","journal-title":"N Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2016.04.023","article-title":"Phase 2 Study of the Safety and Antitumor Activity of Apalutamide(ARN-509), A Potent Androgen Receptor Antagonist, in the High-Risk Nonmetastatic Castration-Resistant Prostate Cancer Cohort","volume":"70","author":"Smitha","year":"2017","journal-title":"Eur Urol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.50.1684","article-title":"Phase I Study of ARN-509, A Novel Antiandrogen, in the Treatment of Castration-Resistant Prostate Cancer","volume":"31","author":"Rathkopf","year":"2013","journal-title":"J Clin Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA: Cancer J Clin"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.75.3657","article-title":"Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial","author":"Kyriakopoulos","year":"2018","journal-title":"J Clin Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-11-3948","article-title":"ARN-509a Novel Antiandrogen for Prostate Cancer Treatment","volume":"72","author":"Clegg","year":"2012","journal-title":"Cancer Res"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1715546","article-title":"Apalutamide Treatment and Metastasis-Free Survival in Prostate Cancer","volume":"378","author":"Smith","year":"2018","journal-title":"N Engl J Med"},{"key":"B13","article-title":"Flare Associated With LHRH-Agonist Therapy","author":"Thompson","year":"2001","journal-title":"Rev Urol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1097\/CAD.0000000000000592","article-title":"Comparison of the Effect of the Antiandrogen Apalutamide (ARN-509) Versus Bicalutamide on the Androgen Receptor Pathway in Prostate Cancer Cell Lines","volume":"29","author":"Koukourakis","year":"2018","journal-title":"Anticancer Drugs"},{"key":"B15","doi-asserted-by":"publisher","first-page":"10094","DOI":"10.1038\/s41598-021-89609-2","article-title":"Abiraterone Acetate Versus Bicalutamide in Combination With Gonadotropin Releasing Hormone Antagonist Therapy for High Risk Metastatic Hormone Sensitive Prostate Cancer","volume":"11","author":"Ueda","year":"2021","journal-title":"Sci Rep"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1177\/1756287215574479","article-title":"Efficacy of Degarelix in Prostate Cancer Patients Following Failure on Luteinizing Hormone-Releasing Hormone Agonist Treatment: Results From an Open-Label, Multicentre, Uncontrolled, Phase II Trial (CS27)","volume":"7","author":"Miller","year":"2015","journal-title":"Ther Adv Urol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198908173210701","article-title":"Prevention of the Transient Adverse Effects of a Gonadotropin-Releasing Hormone Analogue (Buserelin) in Metastatic Prostatic Carcinoma by Administration of an Antiandrogen (Nilutamide)","volume":"321","author":"Kuhn","year":"1989","journal-title":"N Engl J Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1159\/000475159","article-title":"Estramustine Phosphate for Preventing Flare-Up in Luteinizing Hormone-Releasing Hormone Analogue Depot Therapy","volume":"27","author":"Shimizu","year":"1995","journal-title":"Eur Urol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/29.11.562","article-title":"Goserelin Acetate With or Without Antiandrogen or Estrogen in the Treatment of Patients With Advanced Prostate Cancer: A Multicenter, Randomized, Controlled Trial in Japan","volume":"29","author":"Kotake","year":"1999","journal-title":"Jpn J Clin OncoI"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.1994.tb02585.x","article-title":"Endocrine Profiles During Administration of the New non-Steroidal Anti-Androgen Casodex in Prostate Cancer","volume":"41","author":"Verhelst","year":"1994","journal-title":"Clin Endocrinol (Oxford)"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1007\/s12672-015-0226-1","article-title":"A Randomized Control Trial Comparing the Efficacy of Antiandrogen Monotherapy: Flutamide vs. Bicalutamide","volume":"6","author":"Nakai","year":"2015","journal-title":"Hormones Cancer"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-018-3632-6","article-title":"An Open-Label, Multicenter, Phase Ib Study Investigating the Effect of Apalutamide on Ventricular Repolarization in Men With Castration-Resistant Prostate Cancer","volume":"82","author":"Belderbos","year":"2018","journal-title":"Cancer Chemother Pharmacol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2017.04.071","article-title":"Design, Synthesis, and Biological Evaluation of Deuterated Apalutamide With Improved Pharmacokinetic Profiles","volume":"27","author":"Pang","year":"2017","journal-title":"Bioorganic Medicinal Chem Lett"},{"key":"B24","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.ejca.2021.08.032","article-title":"A Phase 2 Randomized Clinical Trial of Abiraterone Plus ADT, Apalutamide, or Abiraterone and Apalutamide in Patients With Advanced Prostate Cancer With non-Castrate Testosterone Levels (LACOG 0415)","volume":"158","author":"Maluf","year":"2021","journal-title":"Eur J Cancer"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/29.11.562","article-title":"Goserelin Acetate With or Without Antiandrogen or Estrogen in the Treatment of Patients With Advanced Prostate Cancer: A Multicenter, Randomized, Controlled Trial in Japan","volume":"29","author":"Kotake","year":"1999","journal-title":"Jpn J Clin OncoI"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198908173210701","article-title":"Prevention of the Transient Adverse Effects of A Gonadotropin-Releasing Hormone Analogue (Buserelin) in Metastatic Prostatic Carcinoma by Administration of an Antiandrogen (Nilutamide)","volume":"321","author":"Kuhn","year":"1989","journal-title":"N Engl J Med"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.cca.2018.07.043","article-title":"Biological Variation Estimates for Prostate Specific Antigen From the European Biological Variation Study; Consequences for Diagnosis and Monitoring of Prostate Cancer","author":"Carobene","year":"2018","journal-title":"Clin Chim Acta"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/sj.pcan.4500649","article-title":"cPSA and fPSA Elimination in African-American Men","volume":"6","author":"Martin","year":"2003","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-021-01914-2","article-title":"ARVib Suppresses Growth of Advanced Prostate Cancer via Inhibition of Androgen Receptor Signaling","volume":"40","author":"Liu","year":"2021","journal-title":"Oncogene"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2020.04.030","article-title":"Apalutamide in Combination With Autophagy Inhibitors Improves Treatment Effects in Prostate Cancer Cells","volume":"38","author":"Eberli","year":"2020","journal-title":"Urol Oncol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-021-01528-1","article-title":"Apalutamide Radio-Sensitisation of Prostate Cancer","volume":"125","author":"Kakouratos","year":"2021","journal-title":"Br J Cancer"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.878264\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,31]],"date-time":"2022-05-31T04:52:31Z","timestamp":1653972751000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.878264\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,31]]},"references-count":31,"alternative-id":["10.3389\/fonc.2022.878264"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2022.878264","relation":{},"ISSN":["2234-943X"],"issn-type":[{"type":"electronic","value":"2234-943X"}],"subject":[],"published":{"date-parts":[[2022,5,31]]},"article-number":"878264"}}